Vabysmo achieved its primary endpoint of non-inferiority to aflibercept in RVO in the BALATON and COMINO clinical trials Vabysmo was generally well tolerated, with a […]
….to further ensure traceability and trust in crucial steps along the pharmaceutical supply chain. • Proof of Concept (PoC) successfully provides primary packaging with a […]
Merck will present 39 abstracts at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). • Company’s scientific leadership […]
…First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment This data suggests the long-term positive […]
MedAlliance SELUTION SLR Receives Coronary FDA IDE Approval Following our communication last week “MedAlliance to be acquired by Cordis”, MedAlliance is pleased to make […]
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, and Meteva AS, a 27.23% shareholder […]
Ad hoc announcement pursuant to Art. 53 LR Q3 sales grew +4% cc1 (-4% USD) Innovative Medicines (IM) sales grew +4% cc (-3% USD), driven […]
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2022 on Monday, November 7th, 2022. BioNTech invites […]
Ad hoc announcement pursuant to Art. 53 LR Phase III APPLY-PNH trial met its two primary endpoints for superiority versus anti-C5 treatment in adult paroxysmal […]
The cobas SARS-CoV-2 Qualitative test is one of the first COVID-19 PCR tests performed on an automated, high throughput platform to receive FDA 510(k) clearance. […]
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) […]
At today’s Capital Markets Day, Merck announced its intention to further expand its leadership in science and technology despite the currently challenging operating environment. • […]
Merck has opened a commercial facility for its new Millipore® CTDMO Services offering at the company’s site in Martillac, France. New 2,700-square-meter facility expands production […]
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2. These patients with HER2 low status may now be eligible […]
Copyright © 2023 | WordPress Theme by MH Themes
